2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyCohort studyBreast cancerInstability scoreGenomic instability scoreGermline BRCA mutation carriersPathologic complete response rateAddition of carboplatinComplete response rateStandard neoadjuvant chemotherapyLymph node statusBRCA mutation carriersGermline BRCA1/2 mutationsNegative breast cancerOverall cohortNode statusTreatment armsHigher oddsMutation carriersBRCA1/2 mutationsResponse rateCarboplatinPARP inhibitorsCancer
2018
Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes
Liao G, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Golshan M, Dai M, Chen T, De-Chian C, Tsai W, Pan C, Hsu K, Kao E, Hsu Y, Chang T, Yu J. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. Journal Of Medical Sciences 2018, 38: 54-61. DOI: 10.4103/jmedsci.jmedsci_105_17.Peer-Reviewed Original ResearchRecurrent-free survivalBreast cancer subtypesLymph node statusLymphovascular invasionOverall survivalImportant prognostic factorLymph nodesPrognostic factorsHuman Investigation CommitteeLuminal HER2 subtypeNode statusHER2 subtypeBreast cancerSignificant differencesCancer subtypesLymph node involvementYear of diagnosisInstitutional review board approvalKaplan-Meier analysisTriple-negative subtypeMultivariate survival analysisCox proportional hazardsDate of deathReview board approvalSignificant independent relationship